HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Emerging HER2+ Breast Cancer Research Uses Innovative Combinations of Standard Agents

August 6th 2024

Sara M. Tolaney, MD, MPH, discusses the HER2-positive breast cancer treatment paradigm and how standard agents may be optimized to improve outcomes.

Revisit Every OncLive On Air Episode From July 2024

July 31st 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in July 2024.

Changes in HER2+ Breast Cancer May Include Tailored Therapy With pCR, Use of T-DXd

July 26th 2024

Adrienne G. Waks, MD, discusses the potential for pCR-guided treatment and highlights therapies for patients with residual disease beyond T-DM1.

Tucatinib Retains its Role in HER2+ Metastatic Breast Cancer, Prompting Questions of T-DXd’s Potential Takeover in the First Line

July 24th 2024

Adrienne G. Waks, MD, details her approach to treatment sequencing in metastatic HER2-positive disease and the potential role of T-DXd in the first line.

Neoadjuvant Therapy Selection: Are Abbreviated Regimens an Option in HER2+ Breast Cancer?

July 23rd 2024

Adrienne G. Waks, MD, parses out recent and upcoming data in HER2+ breast cancer and discusses why abbreviated neoadjuvant regimens are not ready for primetime.

Research Propels Additional Options into the Advanced HER2+ Breast Cancer Armamentarium

July 22nd 2024

Sarah Sammons, MD, discusses the evolving treatment landscape for metastatic HER2-postive breast cancer.

De-Escalation Strategies, Biomarkers Could Refine Treatment Algorithm for Early-Stage HER2+ Breast Cancer

July 20th 2024

Sara M. Tolaney, MD, MPH, discusses the use of HER2-directed therapy in the curative setting for HER2-positive breast cancer.

Dr O'Brien on Breast Cancer Research in Patients With HER2+ Brain Metastases

July 18th 2024

Barbara Jane O’Brien, MD, discusses expanding clinical trial enrollment criteria to include patients with HER2-positive breast cancer brain metastases.

Dr Waks on Key Questions Regarding the First-Line Use of T-DXd in HER2+ Breast Cancer

July 17th 2024

Adrienne G. Waks, MD, discusses implications of the potential use of first-line T-DXd in HER2-positive breast cancer.

TQB2930 is Well Tolerated, Elicits Antitumor Activity in HER2+ Advanced Breast Cancer

July 16th 2024

TQB2930 was well tolerated and generated responses in HER2-positive advanced breast cancer.

Investigational Agents, Clinical Trials for Advanced HER2+ Breast Cancer

July 12th 2024

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss novel agents in the pipeline for patients with advanced HER2-positive breast cancer.

Frequent AEs and Management Approaches for Advanced HER2+ Breast Cancer

July 12th 2024

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss commonly reported adverse effects from HER2-positive breast cancer treatment and appropriate management strategies for them.

Treatment Decisions in Advanced HER2+ Breast Cancer With CNS Metastases

July 12th 2024

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss how to decide on treatment for patients with advanced or metastatic HER2-positive breast cancer who have central nervous system metastases.

Optimal Management Strategies in Advanced HER2+ Breast Cancer

July 12th 2024

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss the various management strategies for treatment of patients with advanced or metastatic HER2-positive breast cancer.

Current Prognosis for Advanced or Metastatic HER2+ Breast Cancer

July 12th 2024

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss the prognosis for patients with advanced or metastatic HER2-positive breast cancer.

FS-1502 Is Safe and Displays Antitumor Activity in Metastatic HER2+ Breast Cancer

July 11th 2024

The HER2-directed ADC FS-1502 was well tolerated and generated early signals of antitumor activity in patients with HER2-expressing breast cancer.

Dr Tarantino on the Safety of T-DXd and T-DM1 in HER2+ Breast Cancer

July 2nd 2024

Paolo Tarantino, MD, discusses updated safety data from the phase 3 DESTINY-Breast03 trial of T-DXd in HER2+ breast cancer.

Dr Waks on Unmet Needs in Patients With HER2+ Breast Cancer

June 26th 2024

Adrienne G. Waks, MD, discusses efforts to address unmet needs in HER2-positive breast cancer.

Intrathecal Dendritic Cells Under Evaluation for Leptomeningeal Disease in TNBC and HER2+ Breast Cancer

June 26th 2024

Peter Forsyth, MD, on the investigation of intrathecal dendritic cells for leptomeningeal disease in triple-negative and HER2-positive breast cancer.

Patient Selection Takes Priority as Standard of Cares Shift in HR+ and HER2+ Breast Cancer

June 23rd 2024

Lauren E. Nye, MD, discusses the use of CDK4/6 inhibitors in HR-positive metastatic breast cancer and the evolution of ADCs in HER2-positive disease.